Improve sleep using vestibular stimulation

Trial ID
NCT06386497
Official Title
Overnight Treatment of Parkinson's Disease Using Vestibular Stimulation From a Rocking Bed (Somnomat Casa) - A Feasibility Study
Goal
Improve sleep using vestibular stimulation
Phase
NA
Status
RECRUITING
Sponsor
Insel Gruppe AG, University Hospital Bern
Study Type
INTERVENTIONAL
Enrollment
15 participants
Conditions
Parkinson Disease
Interventions
Nocturnal translational vestibular stimulation

Plain-Language Summary

It tests whether gentle overnight rocking from a Somnomat Casa bed can improve sleep quality and reduce nighttime fragmentation for people with Parkinson's. The bed delivers slow translational vestibular stimulation to the inner ear, a non-drug way to nudge the brain toward deeper, more consolidated sleep, and the intervention is used while participants stay on their usual Parkinson's, antidepressant, and sleep medications. This is a small feasibility study with about 15 participants, using a noninvasive device and excluding people with bilateral deep brain stimulation. Adults 18 to 85 with Parkinson's by MDS criteria who have poor sleep (PSQI > 5), speak German, are not demented (MoCA ≥ 24), weigh under 150 kg, and have no major psychiatric or other neurological diseases can apply.

Locations

  • Insel Gruppe AG, University Hospital Bern, Bern, Switzerland
  • ETH Zurich, Sensory-Motor Systems Lab, IRIS, Zurich, Switzerland

Frequently Asked Questions

What is this trial testing?
This trial is studying Nocturnal translational vestibular stimulation. It tests whether gentle overnight rocking from a Somnomat Casa bed can improve sleep quality and reduce nighttime fragmentation for people with Parkinson's. The bed delivers slow translational vestibular stimulation to the inner ear, a non-drug way to nudge the brain toward deeper, more consolidated sleep, and the intervention is used while participants stay on their usual Parkinson's, antidepressant, and sleep medications. This is a small feasibility study with about 15 participants, using a noninvasive device and excluding people with bilateral deep brain stimulation. Adults 18 to 85 with Parkinson's by MDS criteria who have poor sleep (PSQI > 5), speak German, are not demented (MoCA ≥ 24), weigh under 150 kg, and have no major psychiatric or other neurological diseases can apply.
Who can participate?
Participants must be between 18 Years and 85 Years.
Where is this trial located?
This trial is recruiting at 2 locations.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 1 year and 9 months.

View on ClinicalTrials.gov